A phase 1 dose-escalation and expansion-cohort study of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients (pts) with advanced solid tumors

被引：0
|
作者：
Shapiro, Geoffrey
Barve, Minal A.
Bhave, Manali A.
Subbiah, Vivek
Uttamsingh, Shailaja
Sharma, Keerti
Andrianova, Lana
Patnaik, Amita
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Mary Crowley Canc Res, Dallas, TX USA
[3] Emory Univ, Sch Med, Atlanta, GA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA
[5] Exelixis Inc, Alameda, CA USA
[6] START, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3176
引用
收藏
页数：1
相关论文
共 50 条
  • [21] MULTICENTER, DOSE-ESCALATION STUDY OF THE INVESTIGATIONAL DRUG TAK-733, AN ORAL MEK INHIBITOR, IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS: PRELIMINARY PHASE 1 RESULTS
    Adjei, A. A.
    LoRusso, P. M.
    Ribas, A.
    Sosman, J. A.
    Dy, G. K.
    Chmielowski, B.
    Lipman, P.
    Zhou, X.
    Gangolli, E.
    Bozon, V.
    ANNALS OF ONCOLOGY, 2012, 23 : 158 - 158
  • [22] A PHASE I DOSE ESCALATION AND EXPANSION STUDY OF INTRATUMORALLY ADMINISTERED CV8102 AS A SINGLE-AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODIES IN PATIENTS WITH ADVANCED SOLID TUMORS
    Eigentler, Thomas
    Heinzerling, Lucie
    Krauss, Juergen
    Weishaupt, Carsten
    Mohr, Peter
    Ochsenreither, Sebastian
    Terheyden, Patrick
    Martin-Liberal, Juan
    Oliva, Marc
    Lebbe, Celeste
    Fluck, Michael
    Brossart, Peter
    Trigo Perez, Jose Manuel
    Bauernfeind, Franz-Georg
    Kays, Sarah-Katharina
    Seibel, Tobias
    Schoenborn-Kellenberger, Oliver
    Stosnach, Claudia
    Daehling, Angelika
    Schmitt-Bormann, Beate
    Gnad-Vogt, Ulrike
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A478 - A479
  • [23] A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors
    Eigentler, Thomas
    Krauss, Juergen
    Schreiber, Jutta
    Weishaupt, Carsten
    Terheyden, Patrick
    Heinzerling, Lucie
    Mohr, Peter
    Weide, Benjamin
    Ochsenreither, Sebastian
    Becker, Juergen
    Bauernfeind, Franz-Georg
    Brossart, Peter
    Funkner, Fatma
    Heidenreich, Regina
    Kays, Sarah-Katharina
    Muth, Anke
    Seibel, Tobias
    Scheel, Birgit
    Schoenborn-Kellenberger, Oliver
    Stosnach, Claudia
    Daehling, Angelika
    Strack, Tanja
    Korolkiewicz, Roman
    Gnad-Vogt, Ulrike
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [24] A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 and BI 754111 in patients (pts) with advanced solid tumors.
    Tolcher, Anthony W.
    Hafez, Navid
    Yamamoto, Noboru
    Park, Jaehong
    Grempler, Rolf
    Lucarelli, Anthony G.
    Lahmar, Mehdi
    Wang, Bushi
    Gounder, Mrinal M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors
    Infante, Jeffrey R.
    Dees, E. Claire
    Olszanski, Anthony J.
    Dhuria, Shyeilla V.
    Sen, Suman
    Cameron, Scott
    Cohen, Roger B.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (28) : 3103 - +
  • [26] A phase 1 study of SY-1365, a selective CDK7 inhibitor, in adult patients with advanced solid tumors
    Tolcher, A.
    Do, K. T.
    di Tomaso, E.
    Waters, N.
    Stephens, K.
    Roth, D. A.
    Shapiro, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
    Li, Huiping
    Liu, Rongrui
    Shao, Bin
    Ran, Ran
    Song, Guohong
    Wang, Ke
    Shi, Yehui
    Liu, Jihong
    Hu, Wenjing
    Chen, Fu
    Liu, Xiaoran
    Zhang, Gairong
    Zhao, Chuanhua
    Jia, Ru
    Wang, Quanren
    Rugo, Hope S.
    Zhang, Yifan
    Li, Guangze
    Xu, Jianming
    CHINESE JOURNAL OF CANCER RESEARCH, 2020, 32 (03) : 370 - +
  • [28] Phase I dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors.
    Sausville, E. A.
    LoRusso, P.
    Carducci, M. A.
    Barker, P. N.
    Agbo, F.
    Oakes, P.
    Senderowicz, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] Phase I dose-escalation study of brostallicin in combination with cisplatin (cDDP) in patients with advanced solid tumors
    Lorusso, D.
    Fornari, G.
    Caponigro, F.
    Quirino, M.
    Merlano, M.
    Airoldi, M.
    Schena, M.
    Jannuzzo, M. G.
    Crippa, S.
    Scambia, G.
    EJC SUPPLEMENTS, 2007, 5 (04): : 111 - 112
  • [30] Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
    A. Craig Lockhart
    Shankar Sundaram
    John Sarantopoulos
    Monica M. Mita
    Andrea Wang-Gillam
    Jennifer L. Moseley
    Stephanie L. Barber
    Alex R. Lane
    Claudine Wack
    Laurent Kassalow
    Jean-François Dedieu
    Alain C. Mita
    Investigational New Drugs, 2014, 32 : 1236 - 1245
12345